MedPath

Preventive Program in Multiple Sclerosis

Not Applicable
Completed
Conditions
Multiple Sclerosis
Registration Number
NCT04667130
Lead Sponsor
Kamila Řasová
Brief Summary

This study monitor the immediate and persistent impact of a preventive complex six-month program specifically developed for newly diagnosed people with multiple sclerosis on fatigue, mental and physical fitness, and quality of life. The study determined whether changes in clinical function are related to changes in neurohormones, and whether the effect of therapy is dependent on the active approach of study participants.

Detailed Description

The patients who were newly diagnosed with MS underwent a six-month preventive comprehensive program, which included individual physiotherapy focused on the treatment of functional disorders of the loco-motor system and therapy on a neurophysiological basis, group psychotherapy and controlled aerobic training. The participants were examined three times - before the start of the physiotherapy program, immediately after its completion and six months apart. Influence on physical fitness (spiroergometric examination), fatigue (Modify Fatigue Impact Scale, fatigue scale for motor and cognitive functions), depression (Beck scale for evaluation of depression), admission of disease RS (Inventory of admission of multiple sclerosis, quality of life) life and selected neurohormones (dehydroepiandrosterone-DHEA, dehydroepiandrosterone sulphate - DHEAS, cortisol).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
17
Inclusion Criteria
  • definite MS
  • stable clinical status in the preceding 3 months
  • imumnomodulatory treatment for at least two years (including glatiramer acetate, interferon beta-1a, 1b, mitoxantrone, fingolimod, natalizumab)
  • Expanded Disability Status Scale (EDSS)≤6
  • predominant motor impartment
  • six months or more without any physiotherapy
  • ability to undergo ambulatory physiotherapy
Exclusion Criteria
  • other neurological disease or conditions disabling movement

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Questionnaires - Beck Depression Inventory Scorechange after six months of the program and after next six moths without therapy is being assessed

questionnaire is divided into thirteen categories and patients select a statement in each category which best fits their current feelings on the scale ranged from 0 (the best feelings) to 3 (the worst feelings). The maximum value of the total scale is 39 and shows the worst feeling of the person.

Questionnaires - The Satisfaction With Life Scalechange after six months of the program and after next six moths without therapy is being assessed

The scale measures the current level of satisfaction with one's own life. Investigators express the extent to which they agree or disagree with the five statements. The rating scale contains 7 points (1- "strongly disagree" and 7 - "strongly agree"). The maximum number of points on the scale is 35 (maximum satisfaction with your life) and the minimum number of points is 5 (dissatisfaction with your life).

Questionnaires - Multiple Sclerosis Acceptance Questionnairechange after six months of the program and after next six moths without therapy is being assessed

This questionnaire consists of 20 statements that relate to the lives of patients with MS. The rating scale has seven points (1- "never pays" to 7 - "always pays"). The minimum value is 20 (minimum adaptation to the diagnosis of MS for a large limitation of the normal life of MS) and the maximum value is 140 points (maximum adaptation to the diagnosis of MS - without the limitation of the normal life of MS) .

Questionnaires - The Fatigue scale for motor and cognitive functionschange after six months of the program and after next six moths without therapy is being assessed

FSMC - is an assessment of MS-related cognitive and motor fatigue. A Likert-type 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question. Thus minimum value is 20 (no fatigue at all) and maximum value is 100 (severest grade of fatigue).

Secondary Outcome Measures
NameTimeMethod
Maximal oxygen uptakechange after six months of the program and after next six moths without therapy is being assessed

VO2 kg-1 \[ VO2max.kg-1 \]

Ventilation capacitychange after six months of the program and after next six moths without therapy is being assessed

Forced vital capacity = FVC \[ l \]

Metabolic utilizationchange after six months of the program and after next six moths without therapy is being assessed

maximal muscle performance = Rmax \[ Watt kg-1 \]

Cortisolchange after six months of the program and after next six moths without therapy is being assessed

levels of cortisol \[ ng/mL \]

Cortizonechange after six months of the program and after next six moths without therapy is being assessed

levels of cortisone\[ ng/mL \]

Dehydroepiandrosterone (DHEA)change after six months of the program and after next six moths without therapy is being assessed

levels of DHEA \[ ng/mL \]

Relative ventilationchange after six months of the program and after next six moths without therapy is being assessed

\[ VEmax.kg-1 \]

7β-hydroxydehydroepiandrosterone (7β-OH-DHEA )change after six months of the program and after next six moths without therapy is being assessed

levels of 7β-OH-DHEA \[ ng/mL \]

7-oxo dehydroepiandrosterone (7-oxo-DHEA )change after six months of the program and after next six moths without therapy is being assessed

levels of 7-oxo-DHEA \[ ng/mL \]

Maximal oxygen pulsechange after six months of the program and after next six moths without therapy is being assessed

VO2 HR-1 kg-1 \[ VO2max.TF-1 \]

Trial Locations

Locations (1)

Kamila Řasová

🇨🇿

Praha, Czechia

Kamila Řasová
🇨🇿Praha, Czechia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.